Evoke Pharma (NASDAQ:EVOK – Get Free Report) announced its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24), Zacks reports. Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%. The company had revenue of $3.31 million during the quarter, compared to analysts’ expectations of $3.08 million.
Evoke Pharma Stock Down 0.8 %
NASDAQ EVOK opened at $3.82 on Friday. Evoke Pharma has a twelve month low of $3.44 and a twelve month high of $12.32. The firm has a market capitalization of $5.68 million, a PE ratio of -0.35 and a beta of 0.12. The stock’s 50 day moving average is $4.53 and its 200 day moving average is $4.71.
Analyst Upgrades and Downgrades
Separately, StockNews.com began coverage on Evoke Pharma in a research note on Wednesday. They set a “sell” rating on the stock.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What Makes a Stock a Good Dividend Stock?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- What Are Earnings Reports?
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
